Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity (NCT06967389)
Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity (MODERN)
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to learn if the drug semaglutide changes markers of disease risk as it relates to weight in children ages 12-15 years old who are obese (class 2 or 3). The main questions it aims to answer are: * How do the rate of weight loss, body mass index (BMI), body composition, heart structure and function, and exercise ability interact with one another in the study population at enrollment? * How do risk markers of disease change over the study in the study participants who are given semaglutides to help with weight loss? * Are there differences in the above factors between males and females and are there key factors to help improve the outcomes? Participants will be given semaglutide for this study. During the course of the study, participants will: * have two cardiac MRI scans OR two cardiac echocardiograms (one before starting semaglutide and one around 12 months after taking the drug) * have body composition and fitness levels assessed twice (before semaglutide and around 12 months after taking it) and have urine specific gravity (USG) measured * have extra blood drawn when labs their doctor orders are already being drawn (once at the beginning of the study, once around 6 months after enrollment, and once at the end of the study) * have follow up visits with the study doctor * be asked to take a pregnancy test if they are female and have started menstruation
Who can join: Review the eligibility criteria below.
Location: University of Kentucky — Lexington, Kentucky
Age range: 12 Years to 17 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of Kentucky — Lexington, Kentucky
📞 Contact the Study Coordinator
Phone: (859) 323-2969
Email: maggie.murphy@uky.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Obesity and Overweight
- Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity — Scottsdale, Arizona
- Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese — Los Angeles, California
- Impact of Chia Seeds on Human Breast Milk Composition — Boston, Massachusetts
- Brain and Behavior Influences on Obesity Development From Infancy Through Childhood — Baltimore, Maryland
- FAMily-centered WEight Loss for Black Adults (FAM WEL B-ing) — Chapel Hill, North Carolina
- Metabotyping of Broccoli Microgreen in Obese Breast Cancer Survivors — Baltimore, Maryland
Explore by condition: All Obesity and Overweight clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.